Cancer Clinical Trials:
Glioblastoma Protocols
LS-P-CENTRIC: Cilengitide for subjects with newly diagnosed GBM and methylated MGMT gene promoter – a multicenter, open-label, controlled Phase III study, testing cilengitide in combination with standard treatment (team with concomitant radiation therapy, following by team maintenance therapy) vs. standard treatment alone
Principal Investigator: Suriya Jeyapalan, MD
Sites: Rhode Island Hospital
RTOG 0825: Phase III Double-Blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma.
Principal Investigator: Brigid O’Connor, MD, PhD
Site: Rhode Island Hospital
RTOG 0929: A Randomized Phase I/II Study of ABT-888 in Combination with Temozolomide in Recurrent (Temozolomide Resistant)
Principal Investigator: Heinrich Elinzano, MD
Sites: Rhode Island Hospital
For more information about these clinical trials and how to participate, please call 401-444-HOPE (4673). For general information about clinical trials please visit the National Cancer Institute.
CBS 60 Minutes Reports on a “Breakthrough” Treatment of GBM Brain Tumors:
What Does Breakthrough Therapy Designation Mean for Duke University Clinical Trial?
Since the news program “60 Minutes” first aired two segments last year that focused on results of an early-phase brain tumor clinical trial taking place at Duke University, there’s been a lot of excitement about the re-engineered poliovirus treatment. Overall, the early analysis demonstrated that patients receiving the therapy were living longer than is typically expected for recurrent GBM patients.
As a result of even more recent, encouraging results, the U.S. Food and Drug Administration (FDA) has recently granted Duke what is known as “Breakthrough Therapy Designation.”
